1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinomaActive, not recruitingPhase 1 / Phase 22025-09-10NCT05845814